Prima BioMed Announces Formation of Clinical Advisory Board
31 Maio 2017 - 9:54PM
Prima BioMed Ltd (ASX:PRR) (NASDAQ:PBMD) (“Prima” or the “Company”)
today announced the formation of a Clinical Advisory Board (CAB) to
serve as a strategic resource to the company as it continues to
advance the clinical development program and commercialisation path
for its lead drug candidate IMP321 for cancer patients worldwide.
The CAB will advise Prima on the regulatory and clinical
development strategy for its Active Immunotherapy PAClitaxel
(AIPAC) clinical trial, which is investigating the safety and
efficacy of IMP321 active immunotherapy in combination with
paclitaxel chemotherapy in patients with hormone receptor-positive
metastatic breast cancer.
Dr. Frédéric Triebel, Chief Scientific Officer & Chief
Medical Officer of Prima, said: “Securing such a distinguished
group of medical professionals is a testament to the growing level
of support for immuno-oncology product candidates. While the
initial focus of the board will be on developing IMP321 in
metastatic breast cancer worldwide, it will also advise us on our
other clinical and pre-clinical programs.”
The newly formed board will be chaired by Pr. Martine Piccart,
who will be joined by Doctor Luc Dirix, Professor David Cameron,
Doctor Samson Fung, and Professor Salah-Eddin Al-Batran.
Professor Martine J. Piccart is professor of
oncology at the Université Libre de Bruxelles (ULB) and Head of the
medicine department at the Institute Jules Bordet, in Brussels,
Belgium. With a primary interest in breast cancer (BC) and drug
development, Prof. Piccart is a leader in international research
collaboration and is the co-principal investigator of several large
clinical trials, including HERA, MINDACT, and ALTTO. She is
co-founder and chair of the Breast International Group (BIG) which
unites more than 50 BC research groups around the world. Prof.
Piccart is the immediate past president of the European CanCer
Organisation (ECCO, 2014-2015). She has also held presidencies of
the European Organisation for the Research and Treatment of Cancer
(EORTC) and the European Society for Medical Oncology (ESMO), and
has served on the American Society of Clinical Oncology Board
(ASCO). She joined the Board of Directors of the AACR in
2017.
Doctor Luc Dirix is Head of Medical Oncology at
the Oncology Center at AZ Sint-Augustinus Hospital in Antwerp,
Belgium. He is a member of the American Society for Cancer
Research, the European Society of Medical Oncology and the European
Organization for Research and Treatment of Cancer. He is
past-chairman and current Board member of the Belgian Society of
Medical Oncology.
Professor David Cameron is the Clinical
Director and Chair of Oncology at The University of Edinburgh
Cancer Research Centre in the UK. He is a member of the American
Society of Clinical Oncology & the European Society for Medical
Oncology, and is active in a number of clinical trials in breast
cancer in the UK and other countries.
Doctor Samson Fung of Fung Consulting in
Germany, provides strategic and operational assistance to
pharmaceutical and biotech companies including Novartis and
Bristol-Myers-Squibb. Dr. Fung is the CEO & Managing Director
of Volvox Therapeutics and a member of the American Society of
Clinical Oncology, the American Society of Clinical Haematology
& the German Society of Pharmaceutical Medicine.
Professor Salah-Eddin Al-Batran is the Medical
Director at the Institute of Clinical Cancer Research in Frankfurt,
Germany. As a haematologist and oncologist, Prof. Al-Batran is on
the Board of the University Cancer Centre in Frankfurt, and Task
Force director for Phase I/II Trials. He is a member of the German
Society of Clinical Oncology, the American Society of Clinical
Oncology, and the European Organisation for Research and Treatment
of Cancer.
About IMP321IMP321, a first-in-class Antigen
Presenting Cell (APC) activator based on the immune checkpoint
LAG-3, represents one of the first proposed active immunotherapy
drugs in which the patient’s own immune system is harnessed to
respond to tumour antigenic debris created by chemotherapy. As an
APC activator IMP321 boosts the network of dendritic cells in the
body that can respond to tumour antigens for a better anti-tumour
CD8 T cell response.
About Prima BioMed
Prima BioMed is listed on the Australian
Securities Exchange and on the NASDAQ in the US. For further
information please visit www.primabiomed.com.au.
For further information please contact:
U.S. Investors:
Matthew Beck, The Trout Group LLC
+1 (646) 378-2933; mbeck@troutgroup.com
Australian Investors/Media:
Mr Matthew Gregorowski, Citadel-MAGNUS
+61 2 8234 0105; mgregorowski@citadelmagnus.com
Immutep Limited (NASDAQ:PBMD)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Immutep Limited (NASDAQ:PBMD)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024